Research Summaries

In a randomized clinical trial presented at Association for Research in Vision and Ophthalmology Annual Meeting, researchers compared an extended period of optical treatment (wearing glasses) with early eye...

This COVID-19 roundup includes coverage of the combination of amubarvimab and romlusevimab to manage COVID-19 infection, the association between COVID-19 and incident diabetes, and the effectiveness of...

The US FDA recently approved a novel treatment for moderate to severe vasomotor symptoms that are caused by menopause.

A team of researchers determined the impact of obstructive sleep apnea and insomnia on cognitive decline in women with multiple sclerosis.

The authors set out to determine implant survivorship and patient satisfaction of robotic-arm—assisted unicompartmental knee arthroplasty at 10-years follow-up.

The FDA has approved the first orally administered treatment for the gut infection—clostridioides difficile.

To guide prevention efforts for fatal poisonings in pediatric patients, the authors of a recent study examined characteristics of death from poisoning in young children within the United States.

In their presentation at the 48th ONS Congress, in San Antonio, Texas, Denise Nicholson BSN, RN and Colleen Nevins DNP, RN, CNE describe the best practices for advance care planning conversations and review...

The FDA’s approval of nalmefene hydrochloride nasal spray marks the first of its kind for health care and community use.

After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.